Novel therapies in osteoporosis – Clinical update – 2025
Dec 1, 2025 · We assess the mechanisms of action, clinical trial outcomes, safety profiles, and practical implementation …
Osteoporosis therapies and their mechanisms of action (Review)
The present review highlighted the causes of osteoporosis and the mechanisms of action underlying the drugs used to treat this …
Osteoporosis treatment: current drugs and future developments
Aug 12, 2024 · This article mainly reviews the research progress of currently approved clinical therapeutic drugs for osteoporosis, …
Romosozumab for the treatment of osteoporosis – a ... - Springer
Nov 2, 2024 · Romosozumab, a new treatment of osteoporosis, is a monoclonal antibody that targets sclerostin and thereby exhibits …
Sequential and combination therapy with romosozumab
Mar 1, 2025 · Romosozumab, an anti-sclerostin antibody, is a novel osteoporosis drug with a dual mechanism of action, promoting …
Combination Therapy of PTH and Antiresorptive Drugs on ... - Frontiers
Jan 27, 2021 · Using recently published literature, we aimed to review the effect of using PTH and antiresorptive drugs as a …
Subcutaneous teriparatide and abaloparatide should be reserved for patients with severe osteoporosis in whom an increase in bone …
FDA SIDE EFFECTS UPDATE: Osteoporosis Drugs and New Bone …
Mar 3, 2026 · New safety advisories and side effect warnings for osteoporosis drugs including Fosamax, Actonel, Reclast, Boniva …
Long-term and sequential treatment for osteoporosis - Nature
Jul 18, 2023 · In this Review, we discuss current pharmaceutical therapy options and goals for adult patients with osteoporosis, the …
Drug therapy for osteoporosis in older adults - The Lancet
Several pharmacological agents are available to lower fracture risk, either by reducing bone resorption or by stimulating bone formation.